| Active ingredient (INN) |
|---|
| Pazopanib |
| Brand names | Teva |
|---|
| Therapeutic category | Auto-created by Pharmac — New Zealand Medicine Supply Disruptions scraper |
|---|
| Controlled substance | No |
|---|
| Marketing-authorisation holders | Novartis Pharmaceuticals Australia Pty Ltd, TEVA PHARMACEUTICALS, INC., TORRENT PHARMACEUTICALS LIMITED, PHARMASCIENCE INC +2 more |
|---|
| Registrations on file | 7 |
|---|
| Patient information leaflet (PIL) | Not on file |
|---|
| Summary of product characteristics (SPC) | Not on file |
|---|
| Product | Strength | Form | Market | MA holder | Status |
|---|---|---|---|---|---|
| VOTRIENT pazopanib | 400 mg | — | 🇦🇺 AU | Novartis Pharmaceuticals Australia Pty Ltd | Active |
| VOTRIENT pazopanib | 200 mg | — | 🇦🇺 AU | Novartis Pharmaceuticals Australia Pty Ltd | Active |
| Pazopanib | 200mg/1 | tablet | 🇺🇸 US | TEVA PHARMACEUTICALS, INC. | Active |
| pazopanib | 400mg/1 | tablet | 🇺🇸 US | TORRENT PHARMACEUTICALS LIMITED | Active |
| Pms-Pazopanib | — | tablet | 🇨🇦 CA | PHARMASCIENCE INC | Active |
| Auro-Pazopanib | — | tablet | 🇨🇦 CA | AURO PHARMA INC | Active |
| Sandoz Pazopanib | — | tablet | 🇨🇦 CA | SANDOZ CANADA INCORPORATED | Cancelled |